Free Trial
NASDAQ:SUPN

Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

Supernus Pharmaceuticals logo
$45.37 +0.30 (+0.67%)
Closing price 04:00 PM Eastern
Extended Trading
$45.37 0.00 (0.00%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)

Key Stats

Today's Range
$44.17
$45.42
50-Day Range
$31.16
$45.37
52-Week Range
$29.16
$45.60
Volume
468,822 shs
Average Volume
1.07 million shs
Market Capitalization
$2.54 billion
P/E Ratio
39.45
Dividend Yield
N/A
Price Target
$41.00
Consensus Rating
Moderate Buy

Company Overview

Supernus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

SUPN MarketRank™: 

Supernus Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat, and ranked 685th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Supernus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Supernus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Supernus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Supernus Pharmaceuticals are expected to decrease by -39.50% in the coming year, from $2.38 to $1.44 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Supernus Pharmaceuticals is 39.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.69.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Supernus Pharmaceuticals is 39.45, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.31.

  • Price to Book Value per Share Ratio

    Supernus Pharmaceuticals has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Supernus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.93% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently decreased by 0.39%, indicating that investor sentiment is improving.
  • Dividend Yield

    Supernus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Supernus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.93% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently decreased by 0.39%, indicating that investor sentiment is improving.
  • News Sentiment

    Supernus Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Supernus Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    Only 2 people have searched for SUPN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Supernus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,617,005.00 in company stock.

  • Percentage Held by Insiders

    Only 8.80% of the stock of Supernus Pharmaceuticals is held by insiders.

  • Read more about Supernus Pharmaceuticals' insider trading history.
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SUPN Stock News Headlines

Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
2 Safe-and-Steady Stocks to Target This Week and 1 We Brush Off
See More Headlines

SUPN Stock Analysis - Frequently Asked Questions

Supernus Pharmaceuticals' stock was trading at $36.16 at the beginning of the year. Since then, SUPN stock has increased by 25.5% and is now trading at $45.37.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced its quarterly earnings data on Monday, November, 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25. The company's quarterly revenue was up 14.2% on a year-over-year basis.
Read the conference call transcript
.

Supernus Pharmaceuticals' top institutional shareholders include Armistice Capital LLC (8.58%), State Street Corp (3.94%), Stephens Investment Management Group LLC (2.82%) and Geode Capital Management LLC (2.50%). Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Frank Mottola, Georges Gemayel, Padmanabh P Bhatt, Jonathan Rubin, Timothy C Dec and Bethany Sensenig.
View institutional ownership trends
.

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
11/04/2024
Today
8/28/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SUPN
CIK
1356576
Employees
580
Year Founded
2005

Price Target and Rating

High Price Target
$46.00
Low Price Target
$36.00
Potential Upside/Downside
-9.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.15
Trailing P/E Ratio
39.45
Forward P/E Ratio
19.06
P/E Growth
N/A
Net Income
$73.86 million
Net Margins
9.70%
Pretax Margin
12.35%
Return on Equity
14.22%
Return on Assets
10.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.58
Quick Ratio
2.43

Sales & Book Value

Annual Sales
$665.13 million
Price / Sales
3.82
Cash Flow
$4.27 per share
Price / Cash Flow
10.63
Book Value
$18.97 per share
Price / Book
2.39

Miscellaneous

Outstanding Shares
56,073,000
Free Float
51,139,000
Market Cap
$2.54 billion
Optionable
Optionable
Beta
0.74

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:SUPN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners